estimates required, page-3

Major events with Dendreon have usually resulted in a significant effect on Prima.

Same old. However we all know the fundamentals for Prima are essentially unchanged.

What has changed is that it is now starkly clear that Prima, as a biotech in research phase, is a high risk speccy.

Many here, and I suspect elsewhere, had forgotten that. I've been criticised in the past on this forum for pointing that out and warning people to "don't bet the farm" on it.

I still have a lot of confidence in the future of Prima and Cvac. That's why I increased my holding by 50% yesterday.

As sure as night follows day, along the way to Phase III results, there will be a continuing roller coaster ride. It goes with the territory.